Navigation Links
BioElectronics Corporation (BIEL) SqueezeTrigger Price is $0.11
Date:2/12/2008

at you undertake. BUYINS.NET, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to BUYINS.NET and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State.

Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. BUYINS.NET does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. BUYINS.NET places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.

Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the
'/>"/>

SOURCE BioElectronics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. BioElectronics Corporation Receives 2007 Economic Development Innovator of the Year Award
2. BioElectronics Corporation Announces Addition of Michael Seidenman, R.Ph. as Vice President of Sales
3. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
4. Brooke Franchise Corporation Announces Selected July Results
5. MedThink Communications Retained by NanoBio Corporation
6. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
7. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
8. Memry Corporation Announces Fiscal Fourth Quarter and 2007 Year End Earnings Release and Conference Call
9. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
10. LifeQuest World Corporation Proud Contributor to Dietary Supplement Education Alliance (DSEA)
11. DTI Medical Corporation Announces Reverse Split and Other Corporate Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2008)... Dr. Stephen Cohen Hired As New CEO, ATLANTA,...r Group,(GMCG) announced today that MELCO Investme...ment fund, has signed on as a key partner with a,s...the investment, GMCG has,also appointed Dr. Stephe...,surgeons, as its new CEO., (Photo: http://www.n...
(Date:7/23/2008)...d and Medicare Rules Highlighted; a Focus on Preve...tions, LANSING, Mich., July 23 /PRNewswire/ -- Th...&PSI), a national leader in clinical risk manageme... care institutions and,providers, today announced ... conference., The conference will take place Sept...
(Date:7/23/2008)... Michigan Takes Top Honors as the #1 Healthiest Ci...PRNewswire-USNewswire/ -- AARP The Magazine, the,d...largest-circulation,magazine with more than 34 mil...st cities to live and retire in with Ann Arbor, MI...go, ND taking the top five rankings.,Featured in t...
(Date:7/23/2008)...a., July 23 /PRNewswire-USNewswire/ -- The HealthC...m ) today announced that Dr. Fran Cogen,MD, direc...am at Children,s,National Medical Center, will pro...om, a site offering connections to a community of ...priate consultation by a dietician, social,worker,...
Breaking Medicine News(10 mins):Health News:Greater Medical Center Group Receives Major Funding From MELCO Investments 2Health News:Greater Medical Center Group Receives Major Funding From MELCO Investments 3Health News:The Risk Management and Patient Safety Institute Announces 2008/2009 Annual Risk Management Conference, Dates 2Health News:AARP the Magazine Names the Top 10 Healthiest Places to Live in America 2Health News:AARP the Magazine Names the Top 10 Healthiest Places to Live in America 3Health News:AARP the Magazine Names the Top 10 Healthiest Places to Live in America 4Health News:AARP the Magazine Names the Top 10 Healthiest Places to Live in America 5Health News:Children's National Medical Center Program Director to Provide Expertise to DiabeTeens.com, The HealthCentral Network's Teen Diabetes Site 2
...n often disabling condition that affects primarily...ted fatigue // that cannot be overcome with rest a... of the condition is unknown, and there are no dia...hat children who have sedentary behaviors are at i...
...n between the use of two of the most common medica... risk for // bone fractures. Beta-blockers are com...e heart failure, chest pain, and abnormal heart rh...e drugs to prevent a second attack. Diuretics are ...
...Wake Forest University Baptist Medical Center rese...r research in monkeys suggested //that the type of...t heart attack severity. At an annual meeting of...in Washington, D.C. today, Dr. J. Koudy Williams w...
...essive eye disease targeting the light-collecting ...orldwide and can cause // vision loss. Researchers...osa, the addition of docosahexaenoic acid to vitam...enefits, according to a recent study. Researchers ...
Other Medicine News:Health News:Hormone therapy may affect heart attack severity in women 2
(Date:7/22/2008)...ISBANE, Australia, July 22 /PRNewswire-FirstCall/ ... yesterday, the Board of Progen,Pharmaceuticals Li...t it,had discontinued the PI-88 phase 3 study in l...ion to develop its existing portfolio of compounds...itional compounds and,opportunities through Merger...
(Date:7/22/2008)...test awards under Therapeutics Development Initiat...tions to 23; next deadline January 20,2009, NEW ...f its mission to,speed delivery of transformative ... Michael J. Fox Foundation for Parkinson,s Researc... industry research teams. The awards,were granted ...
(Date:7/22/2008)...te-of-the-Art PET Study Confirms Tyrima Exhibits E...operties - - Results Support Initiation of P..., N.C., July 22 /- CeNeRx BioPharma,...ercializing innovative,treatments for diseases of ...to advance its lead candidate Tyrima(TM) into Phas...
(Date:7/22/2008)...UTH SAN FRANCISCO, Calif., July 22 /-...it has completed patient enrollment,in its Phase 1...lity and,ammonia scavenging effects of HPN-100 (fo...nylbutyrate) in patients with urea cycle disorders...ults in the fourth quarter,of this year., (Logo: ...
Breaking Medicine Technology:Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 3Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 2Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 3CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 2CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 3CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 4Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 2Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 3GlycoMark Blood Test Included in Global Diabetes Care Guidelines as Emerging Technology 1940 1GlycoMark Blood Test Included in Global Diabetes Care Guidelines as Emerging Technology 1940 2GlycoMark Blood Test Included in Global Diabetes Care Guidelines as Emerging Technology 1940 3Highlights of Economic and Business Growth in the Tampa Bay Region 800 1Highlights of Economic and Business Growth in the Tampa Bay Region 800 2Highlights of Economic and Business Growth in the Tampa Bay Region 800 3Highlights of Economic and Business Growth in the Tampa Bay Region 800 4Poll reveals public awareness of nanotech stuck at low level 1936 1Poll reveals public awareness of nanotech stuck at low level 1936 2Poll reveals public awareness of nanotech stuck at low level 1936 3Pelosi 3A Mr President Drop the Partisan Rhetoric Put Down the Veto Pen 1933 1
... - Dynogen,Pharmaceuticals, Inc. reported positive...controlled Phase 1b trial of DDP733 for,gastroesop...ed to,demonstrate proof-of-concept for DDP733 as a...dose of DDP733 achieved,statistical significance o...n the number of reflux events and was safe and wel...
... 2007 - Gilead,Sciences, Inc. (Nasdaq:GILD) today ...al evaluating the company,s once-daily,anti-HIV dr...vir,DF) 300 mg as a potential treatment for chroni...ry efficacy endpoint. The study shows,that Viread ...ral,drug Hepsera(R) (adefovir dipivoxil) among pat...
Other Medicine Technology:Dynogen Reports Positive Results in Phase 1B GERD Study 2Dynogen Reports Positive Results in Phase 1B GERD Study 3Dynogen Reports Positive Results in Phase 1B GERD Study 4Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 2Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 3Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 4Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 5Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 6Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 7
...P Laboratories is a national reference laboratory ...search and development. ARUP offers an extensive t...s in clinical and anatomic pathology. Owned by the...clude more than half of the nation's university te...
...P Laboratories is a national reference laboratory ...search and development. ARUP offers an extensive t...s in clinical and anatomic pathology. Owned by the...clude more than half of the nation's university te...
...P Laboratories is a national reference laboratory ...search and development. ARUP offers an extensive t...s in clinical and anatomic pathology. Owned by the...clude more than half of the nation's university te...
...P Laboratories is a national reference laboratory ...search and development. ARUP offers an extensive t...s in clinical and anatomic pathology. Owned by the...clude more than half of the nation's university te...
Medicine Products: